Le Lézard
Classified in: Business
Subjects: ERN, MAT

SNDL Reports Second Quarter 2023 Financial and Operational Results


The Company achieves record net revenue and gross margin results since its inception

CALGARY, AB, Aug. 14, 2023 /PRNewswire/ - SNDL Inc. (NASDAQ: SNDL) ("SNDL" or the "Company") reported its financial and operational results for the second quarter ended June 30, 2023. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.

SNDL has also posted a supplemental investor presentation on its website, which can be found at https://sndl.com.

SECOND QUARTER 2023 FINANCIAL AND OPERATIONAL HIGHLIGHTS

"Our incredible two-year journey from less than $10 million of net revenue and negative gross margin in Q2 2021 to our current trajectory of reaching an expected $1 billion in annual revenue and continued gross margin growth in 2023 is a testament to our team's commitment to becoming a leader in Canadian regulated products," said Zach George, Chief Executive Officer of SNDL. "We have taken decisive steps to simplify operations throughout our business segments with a sharp focus on the goal of reaching profitability in 2024. In Liquor Retail, we are capitalizing on margin accretive product opportunities and modest expansion. In Cannabis Retail, our data licensing program is driving improved profitability and supplier relationships, and we look to enhance consumer engagement through new loyalty capabilities. In our Cannabis Operations, we have taken aggressive cost-cutting measures, streamlined manufacturing operations, and reduced reliance on high-cost cultivation. During this process, we have maintained cannabis sales momentum and are actively exploring B2B and international opportunities. We have also simplified our investment portfolio by divesting from securities, prioritizing the opportunity to return capital to our shareholders."

"Over the last two years, SNDL has grown both organically and by acquisition while our leaders have implemented bold changes throughout the business," added George. "We believe that we now have the requisite scale and platform optionality to create sustainable shareholder value. We expect our Canadian retail network to continue to grow at a modest pace while our internal focus on optimization is in the early stages of producing tangible results. We look forward to updating investors on the closing of the Nova transaction, and events related to our SunStream portfolio as we focus on delivering improved performance in the second half of 2023."

SECOND QUARTER 2023 KEY FINANCIAL METRICS

OPERATING SEGMENTS









($000s)


Liquor
Retail

Cannabis
Retail

Cannabis
Operations

Investments

Corporate


Total

Three months ended June 30, 2023







Net revenue


151,690

71,881

20,940

?

?


244,511

Gross margin


35,360

17,780

(1,207)

?

?


51,933

Earnings (loss) from Operations


8,207

2,340

(14,134)

(1,660)

(24,242)


(29,489)










Three months ended June 30, 2022









Net revenue


148,637

63,494

11,564

?

?


223,695

Gross margin


33,528

13,897

(4,346)

?

?


43,079

Earnings (loss) from Operations


11,288

1,476

(8,293)

(69,973)

(15,914)


(81,416)

 

SECOND QUARTER 2023 RESULTS

SNDL's business is operated and reported in four segments: Liquor Retail, Cannabis Retail, Cannabis Operations and Investments. 

Liquor Retail

SNDL is Canada's largest private sector liquor retailer, operating 170 locations, predominantly in Alberta, under its three retail banners: "Wine and Beyond", "Liquor Depot" and "Ace Liquor".

Cannabis Retail

With its ownership interest in Nova, SNDL is Canada's largest private-sector cannabis retailer, operating 196 locations under its four retail banners: Value Buds, Spiritleaf, Superette, and Firesale Cannabis. SNDL's Cannabis Retail strategy is based on several factors, including the quality of its store locations, the range of products it offers, and the unique experiences it provides customers. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.

On July 25, 2023, SNDL and Nova announced that while all other provincial approvals have been received, the continued review by one provincial regulator has necessitated the extension of the outside date for the closing of the previously-announced strategic partnership (the "Transaction"). SNDL and Nova anticipate that the Transaction will close on or before August 25, 2023, subject to the receipt of regulatory approval and the amendment to certain terms of the Transaction that are mutually satisfactory to SNDL and Nova.

Cannabis Operations

SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities, premium cultivation and manufacturing facilities, the Cannabis Operations segment is a key enabler of SNDL's vertical integration strategy.

Investments


Three months ended
June 30


Six months ended
June 30

($000s)

2023

2022


2023

2022

Interest and fee revenue






Interest revenue from investments at amortized cost

922

818


1,928

1,813

Interest and fee revenue from investments at Fair
Value Through Profit or Loss

250

543


874

2,659

Interest revenue from cash

2,014

1,216


4,595

1,966

 Total interest and fee revenue

3,186

2,577


7,397

6,438

Investment revenue (loss)






Realized (losses) gains

(48,988)

265


(92,792)

389

Unrealized gains (losses)

45,182

(35,338)


84,100

(53,172)

 Total investment revenue/(loss)

(3,806)

(35,073)


(8,692)

(52,783)







Share of profit (loss) of equity-accounted investees

(936)

(37,978)


8,580

(33,887)

Total investment activities

(1,556)

(70,474)


7,285

(80,232)

 

Liquidity Position

STRATEGIC AND ORGANIZATIONAL UPDATE

SNDL remains focused on building long-term shareholder value through vertical integration, the accretive deployment of cash resources, expansion of its retail distribution network, the further streamlining of the Company's operating structure, and enhanced offerings of high-quality brands within the Liquor Retail, Cannabis Retail and Cannabis Operations segments.

Integration Initiatives

The Company has achieved $18.2 million in annualized cost savings since the Valens acquisition in January 2023. These initiatives surpass the Company's original $10 million cost savings target. Most of the cost savings have been realized through SG&A, public company costs, as well as supply chain consolidation and operational efficiency. By 2024, run-rate synergies are expected to exceed $30 million annually, and proceeds from asset sales are expected to total $9 million.

The integration work has allowed the Company to undertake a comprehensive organizational design update, restructuring certain departments to achieve scale, support growth, and reinforce key initiatives. The organizational design work supports a more efficient structuring of SNDL's shared service teams to realize additional cost savings and enable targeted focus on key initiatives, such as loyalty, e-commerce, increasing market share within owned retail, and manufacturing, cultivation and processing improvements.

The Company's integration initiatives are critical to SNDL's vision of establishing Canada's largest regulated products platform and generating sustainable free cash flow.

SNDL's strategy is predicated on the below key objectives:

This press release is intended to be read in conjunction with the Company's Financial Statements and Notes for the period ended June 30, 2023, and the accompanying Management's Discussion and Analysis ("MD&A"). These reports are available under the Company's profile on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.

CONFERENCE CALL

The Company will hold a conference call and webcast at 10:30 a.m. EST (8:30 a.m. MST) on Monday, August 14, 2023.

WEBCAST ACCESS

To access the live webcast of the call, please visit the following link:
https://services.choruscall.ca/links/sndl2023q2.html

REPLAY

A telephone replay will be available for one month. To access the replay, dial:
Canada/USA Toll Free: 1-800-319-6413 or International Toll: +1-604-638-9010
When prompted, enter Replay Access Code: 0323#
The webcast archive will be available for three months via the link provided above.

ABOUT SNDL INC. 

SNDL is a public company whose shares are traded on the Nasdaq under the symbol "SNDL."

SNDL is the largest private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Firesale Cannabis. SNDL is a licensed cannabis producer and one of the largest vertically integrated cannabis companies in Canada specializing in low-cost biomass sourcing, premium indoor cultivation, product innovation, low-cost manufacturing facilities, and a cannabis brand portfolio that includes Top Leaf, Contraband, Citizen Stash, Sundial Cannabis, Palmetto, Bon Jak, Spiritleaf Selects, Versus Cannabis, Value Buds, Vacay, Grasslands and Superette. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry.?For more information on SNDL, please go to?https://sndl.com/.

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company's operational goals, demand for the Company's products, the Company's ability to achieve profitability or its goal of sustainable, positive gross margin and positive free cash flow,?the development of the legal cannabis industry, performance of the Company's investments, including through the SunStream joint venture, any potential forms of shareholder value creation, the ability to realize expected cost savings and the expansion of product offerings, brand and market share and retail networks, and the closing, integration and realization of expected benefits of, as applicable, the acquisition of The Valens Company, Zenabis and Superette. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate",?"likely", "outlook", "forecast",?"may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are?made and?are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see "Item 3.D.?Risk Factors" in the?Company's annual report on Form 20-F, filed with the Securities and Exchange Commission ("SEC") on April 24, 2023, and the risk factors included in our other SEC filings for?a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether?as a result of?new information, future events or otherwise, except as expressly required by applicable law.

Condensed Consolidated Interim Statement of Loss and Comprehensive Loss
(Unaudited - expressed in thousands of Canadian dollars, except per share amounts)



Three months ended
June 30


Six months ended
June 30



2023


2022


2023


2022

Gross revenue


257,425


227,557


470,324


247,684

Excise taxes


12,914


3,862


23,361


6,392

Net revenue


244,511


223,695


446,963


241,292

Cost of sales


188,922


174,291


347,071


188,617

Inventory impairment and obsolescence


4,291


3,871


13,468


5,852

Gross margin before fair value adjustments


51,298


45,533


86,424


46,823

Change in fair value of biological assets


(1,413)


(388)


(4,948)


3,302

Change in fair value realized through inventory


2,048


(2,066)


2,998


(3,627)

Gross margin


51,933


43,079


84,474


46,498










Interest and fee revenue


3,421


2,577


7,632


6,438

Investment loss


(4,020)


(35,073)


(9,189)


(52,783)

Share of profit (loss) of equity-accounted investees


(936)


(37,978)


8,580


(33,887)










General and administrative


52,727


40,293


101,300


50,975

Sales and marketing


4,104


3,132


7,490


4,243

Research and development


20


390


160


485

Depreciation and amortization


13,443


8,800


29,911


9,539

Share-based compensation


3,893


438


6,102


4,642

Restructuring costs


4,042


(882)


5,578


(882)

Asset impairment


1,658


1,850


2,465


1,850

Loss from operations


(29,489)


(81,416)


(61,509)


(104,586)










Transaction costs


(173)


7,938


(2,213)


1,457

Finance costs, net


(2,458)


(26,505)


(7,631)


(26,444)

Change in estimate of fair value of derivative warrants


2,240


23,656


7,042


15,356

Foreign exchange gain (loss)


(31)


161


(194)


11

Gain (loss) on disposition of assets


(77)


402


(261)


402

Loss before income tax


(29,988)


(75,764)


(64,766)


(113,804)

Income tax recovery


?


1,791


?


1,791

Net loss from continuing operations


(29,988)


(73,973)


(64,766)


(112,013)

Net loss from discontinued operations


(3,170)


?


(4,535)


?

Net loss


(33,158)


(73,973)


(69,301)


(112,013)










Equity-accounted investees - share of other
comprehensive income (loss)


(11,621)


12,727


(12,006)


5,994

Gain on translation of foreign operations


(5)


?


?


?

Comprehensive loss


(44,784)


(61,246)


(81,307)


(106,019)










Net loss from continuing operations attributable to:









Owners of the Company


(29,350)


(73,301)


(63,553)


(111,205)

Non-controlling interest


(638)


(672)


(1,213)


(808)



(29,988)


(73,973)


(64,766)


(112,013)

Net income (loss) attributable to:









Owners of the Company


(32,520)


(73,301)


(68,088)


(111,205)

Non-controlling interest


(638)


(672)


(1,213)


(808)



(33,158)


(73,973)


(69,301)


(112,013)

Comprehensive income (loss) attributable to:









Owners of the Company


(44,146)


(60,574)


(80,094)


(105,211)

Non-controlling interest


(638)


(672)


(1,213)


(808)



(44,784)


(61,246)


(81,307)


(106,019)

 

 

Condensed Consolidated Interim Statement of Financial Position
(Unaudited - expressed in thousands of Canadian dollars)

As at


June 30, 2023


December 31, 2022






Assets





Current assets





Cash and cash equivalents


185,455


279,586

Restricted cash


19,456


19,338

Marketable securities


3,535


21,926

Accounts receivable


32,661


22,636

Biological assets


1,330


3,477

Inventory


160,407


127,782

Prepaid expenses and deposits


21,792


10,110

Investments


23,038


6,552

Assets held for sale


8,391


6,375

Net investment in subleases


3,656


3,701



459,721


501,483

Non-current assets





Long-term deposits


9,766


8,584

Right of use assets


136,947


134,154

Property, plant and equipment


181,841


143,409

Net investment in subleases


18,918


19,618

Intangible assets


74,446


74,885

Investments


9,638


90,702

Equity-accounted investees


532,818


519,255

Goodwill


147,680


67,260

Total assets


1,571,775


1,559,350






Liabilities





Current liabilities





Accounts payable and accrued liabilities


62,557


48,153

Lease liabilities


35,982


30,206

Derivative warrants


3,960


11,002



102,499


89,361

Non-current liabilities





Lease liabilities


136,136


139,625

Other liabilities


5,252


2,709

Total liabilities


243,887


231,695






Shareholders' equity





Share capital


2,365,845


2,292,810

Warrants


2,260


2,260

Contributed surplus


73,636


68,961

Contingent consideration


2,279


2,279

Accumulated deficit


(1,156,279)


(1,091,999)

Accumulated other comprehensive income


20,182


32,188

Total shareholders' equity


1,307,923


1,306,499

Non-controlling interest


19,965


21,156

Total liabilities and shareholders' equity


1,571,775


1,559,350

 

 

Condensed Consolidated Interim Statement of Cash Flows
(Unaudited - expressed in thousands of Canadian dollars)


Three months ended
June 30


Six months ended
June 30


2023

2022


2023


2022

Cash provided by (used in):







Operating activities







Net loss for the period

(33,158)

(73,973)


(69,301)


(112,013)

Adjustments for:







Income tax recovery

?

(1,791)


?


(1,791)

Interest and fee revenue

(3,421)

(2,577)


(7,632)


(6,438)

Change in fair value of biological assets

1,413

388


4,948


(3,302)

Share-based compensation

3,893

438


6,102


4,642

Depreciation and amortization

14,674

10,538


32,933


12,977

Loss (gain) on disposition of assets

77

(402)


261


(402)

Inventory obsolescence

4,291

3,871


13,468


5,852

Finance costs

2,458

26,505


7,631


26,444

Change in estimate of fair value of derivative warrants

(2,240)

(23,656)


(7,042)


(15,356)

Unrealized foreign exchange loss (gain)

(72)

19


(24)


35

Asset impairment

1,658

1,850


2,465


1,850

Share of (profit) loss of equity-accounted investees

936

37,978


(8,580)


33,887

Loss on settlement of marketable securities

48,988

?


92,792


?

Unrealized (gain) loss on marketable securities

(44,968)

35,338


(83,603)


53,172

Additions to marketable securities

?

(2,899)


?


(3,500)

Proceeds from settlement of marketable securities

3,437

?


3,463


?

Income distributions from equity-accounted investees

?

?


?


685

Interest received

3,217

2,084


6,920


5,799

Change in non-cash working capital

(14,193)

(31,584)


(56,755)


(46,434)

Net cash used in operating activities from continuing operations

(13,010)

(17,873)


(61,954)


(43,893)

Net cash provided by operating activities from discontinued operations

4,167

?


4,314


?

Net cash used in operating activities

(8,843)

(17,873)


(57,640)


(43,893)

Investing activities







Additions to property, plant and equipment

(1,247)

(3,554)


(2,641)


(4,535)

Additions to intangible assets

(39)

1


(56)


(55)

Additions to investments

125

337


(702)


(14,094)

Additions to equity-accounted investees

(9,443)

(36,880)


(16,989)


(94,200)

Proceeds from disposal of property, plant and equipment

55

4,000


137


4,000

Acquisitions, net of cash acquired

?

?


3,695


(31,149)

Change in non-cash working capital

1,586

294


1,127


259

Net cash used in investing activities from continuing operations

(8,963)

(35,802)


(15,429)


(139,774)

Net cash used in investing activities from discontinued operations

?

?


?


?

Net cash used in investing activities

(8,963)

(35,802)


(15,429)


(139,774)

Financing activities







Change in restricted cash

(76)

2,541


(118)


7,607

Payments on lease liabilities, net

(10,116)

(9,177)


(19,607)


(9,624)

Repurchase of common shares, net of costs

?

(2,053)


(1,536)


(2,053)

Repayment of long-term debt

?

?


?


(10,000)

Change in non-cash working capital

200

2,170


199


2,116

Net cash used in financing activities from continuing operations

(9,992)

(6,519)


(21,062)


(11,954)

Net cash used in financing activities from discontinued operations

?

?


?


?

Net cash used in financing activities

(9,992)

(6,519)


(21,062)


(11,954)

Change in cash and cash equivalents

(27,798)

(60,194)


(94,131)


(195,621)

Cash and cash equivalents, beginning of period

213,253

422,824


279,586


558,251

Cash and cash equivalents, end of period

185,455

362,630


185,455


362,630

 

SPECIFIED FINANCIAL MEASURES

Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures provided by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS.?These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company's operating results in the same manner as the management team. 

ADJUSTED EBITDA

Adjusted EBITDA is a non-IFRS measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors,?analysts,?and others?to aid?in understanding and evaluating the Company's operating results in?a manner similar to its management team. Adjusted EBITDA is defined as net income (loss) from continuing operations before finance costs, depreciation and amortization, accretion expense, income tax recovery and excluding changes in fair value of biological assets, changes in fair value realized through inventory, unrealized foreign exchange gains or losses, unrealized gains or losses on marketable securities, changes in fair value of derivative warrants, share-based compensation expense, asset impairment, gain or loss on disposal of property, plant and equipment, cost of sales non-cash component, inventory impairment (recovery) and obsolescence, restructuring costs and transaction costs. The Company presents both consolidated or total Adjusted EBITDA and Adjusted EBITDA by operating segment.

OPERATING SEGMENTS






($000s)

Liquor
Retail

Cannabis
Retail

Cannabis
Operations

Investments

Corporate

Total

Three months ended June 30, 2023







Net earnings (loss)

6,714

1,221

(13,831)

(1,917)

(22,175)

(29,988)

Adjustments







Finance costs

1,490

1,111

(400)

257

?

2,458

Change in estimate of fair value of
derivative warrants

?

?

?

?

(2,240)

(2,240)

Depreciation and amortization

8,161

3,361

650

?

1,271

13,443

Change in fair value of biological assets

?

?

1,413

?

?

1,413

Change in fair value realized through
inventory

?

?

(2,048)

?

?

(2,048)

Unrealized foreign exchange (gain) loss

(2)

?

(70)

?

?

(72)

Unrealized (gain) loss on marketable
securities

?

?

214

(45,182)

?

(44,968)

Realized loss on marketable securities

?

?

?

49,093

?

49,093

Share-based compensation

?

15

?

?

3,878

3,893

Asset impairment

?

458

1,200

?

?

1,658

Loss (gain) on disposition of PP&E

?

5

72

?

?

77

Cost of sales non-cash component (1)

?

?

969

?

?

969

Inventory impairment (recovery) and
obsolescence

?

?

4,291

?

?

4,291

Restructuring costs

?

?

1,282

?

2,760

4,042

Transaction costs

?

?

?

?

173

173

Adjusted EBITDA

16,363

6,171

(6,258)

2,251

(16,333)

2,194

 (1) Cost of sales non-cash component is comprised of depreciation expense

 

 

OPERATING SEGMENTS






($000s)

Liquor
Retail

Cannabis
Retail

Cannabis
Operations

Investments

Corporate

Total

Three months ended June 30, 2022







Net earnings (loss)

8,379

447

(8,036)

(90,487)

15,724

(73,973)

Adjustments







Finance costs

2,874

1,070

195

22,305

61

26,505

Change in estimate of fair value of
derivative warrants

?

(56)

?

?

(23,600)

(23,656)

Depreciation and amortization

5,315

3,370

?

?

115

8,800

Income tax recovery

?

?

?

(1,791)

?

(1,791)

Change in fair value of biological assets

?

?

388

?

?

388

Change in fair value realized through
inventory

?

?

2,066

?

?

2,066

Unrealized foreign exchange (gain) loss

9

?

10

?

?

19

Unrealized (gain) loss on marketable
securities

?

?

?

35,338

?

35,338

Share-based compensation

?

(180)

?

?

618

438

Asset impairment

?

?

1,850

?

?

1,850

Loss (gain) on disposition of PP&E

35

15

(452)

?

?

(402)

Cost of sales non-cash component (1)

?

?

3,440

?

?

3,440

Inventory impairment (recovery) and
obsolescence

?

?

3,871

?

?

3,871

Restructuring costs

?

?

?

(882)

?

(882)

Transaction costs

?

?

?

?

(7,938)

(7,938)

Adjusted EBITDA

16,612

4,666

3,332

(35,517)

(15,020)

(25,927)

(1) Cost of sales non-cash component is comprised of depreciation expense

 

SOURCE Sundial Growers Inc.


These press releases may also interest you

at 01:35
PalawanPay, a leading e-wallet solution from the Palawan Group of Companies, has partnered with CleverTap, the all-in-one engagement platform, to enhance customer engagement, drive personalization, and fuel significant growth....

at 01:30
In this 29th Annual Report, Artprice by Artmarket presents and analyzes a denser-than-ever Contemporary and Ultra-Contemporary Art Market (see methodology at the end of the press release) with the opening of Frieze London this Wednesday, October 9,...

at 00:01
Mews , a cloud SaaS and fintech platform that serves the hospitality industry, has announced today the appointment of Steve Cakebread to the company's board....

at 00:00
Research by RepRisk reveals a 12% year-on-year decrease of companies linked to greenwashing, signaling a major shift in corporate behavior Despite an overall decline, high-risk cases of greenwashing surged by over 30%.Nearly 30% of companies linked...

at 00:00
IDA, a Hong Kong-based fiat-referenced stablecoin issuer, is integrating Chainlink's industry-standard services for tokenized assets. Those include Chainlink Proof of Reserve (PoR) for verifying asset collateralization and the Chainlink Cross-Chain...

8 oct 2024
DAHON, a global leader in folding bikes, and RoyalBaby, a global leader in children's bikes, announced a strategic partnership during a press conference at the Shangri-La Hotel in Beijing, China, on August 9, 2024. This strong alliance between DAHON...



News published on and distributed by: